PDF(Pubmed)
Abstract：
Substantial survival benefits exist for patients with early-stage breast cancer who undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefits exist with ovarian suppression plus multiple adjuvant therapy which provides a new treatment option that reduces the risk of recurrence in early breast cancer. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at this practical consensus recommendations for the benefit of community oncologists.
摘要：
对于接受单模式卵巢抑制治疗的早期乳腺癌患者，存在显著的生存益处。但它的价值是不确定的。专家肿瘤学家进行了讨论，以确定卵巢抑制加多种辅助治疗是否存在额外的益处，这提供了一种新的治疗选择，可降低早期乳腺癌的复发风险。该专家组使用了已发表文献中的数据，为社区肿瘤学家的利益，一大群学术肿瘤学家的实践经验和意见，以达成这一实际共识建议。
